Aegis Capital Corp. Reiterates Buy Rating, $30 PT on Amarin Corporation plc Following Release of Vascepa Briefing Documents

Loading...
Loading...
In a report published Monday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating and $30.00 price target on
Amarin Corporation plc
AMRN
. In the report, Aegis Capital Corp. noted, “On Friday, October 11, 2013, the FDA released briefing documents for the upcoming advisory committee meeting to consider Amarin's lead drug Vascepa (icosapent ethyl) for the treatment of mixed dyslipidemia. Investors elected to drive Amarin shares to a new 52-week low on sentiment that comments made in the briefing package by FDA staffers were indicative of a negative outcome for the panel vote, which is slated to occur on Wednesday, October 16. In our view, the briefing documents were not anywhere near as negative as initial commentary would have investors believe. Furthermore, we remain confident that the panel vote is likely to ratify our view that Vascepa is a safe and effective drug for the treatment of mixed dyslipidemia, and that new and efficacious approaches for the achievement of triglyceride-lowering in patients with mixed dyslipidemia are sorely needed. In anticipation of a positive panel vote on Wednesday of this week and subsequent approval of Vascepa™ for mixed dyslipidemia in December 2013, we reiterate our Buy rating and 12-month price target of $30.00 on Amarin shares.” Amarin Corporation plc closed on Friday at $5.09.
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsAegis Capital Corp.Raghuram Selvaraju
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...